A Phase II Study of the Polyamine Analog N,N- Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer

Purpose: Polyamines are ubiquitous intracellular polycationic molecules essential for cell growth and differentiation. Polyamine analogs down-regulate ornithine decarboxylase, induce spermidine/spermine N-acetyltransferase, deplete natural polyamine pools, inhibit growth, and induce programmed cell death in breast cancer models. This study evaluated the activity of the first-generation analog DENSpm in women with metastatic breast cancer. Experimental Design: The overall accrual goal was 34 patients (30 evaluable) in a two-stage design. The second stage of accrual was to proceed if >2 among first 15 evaluable patients were progression free at 4 months. The primary objective was to determine whether >20% of metastatic breast cancer patients treated with DENSpm as secondor third-line therapy remained progression free after 4 months. Results: Sixteen patients (median age, 52 years; range, 34–65; median performance status, 1; range, 0–1) enrolled in the first stage received 43 cycles (median, 2; range, 1–6) of 100 mg/m DENSpm as a 15-min infusion i.v. on days 1–5 every 21 days. All 16 patients were evaluable for toxicity; 15 were evaluable for response. All patients had disease progression by 4 months, and the study closed after the first stage of accrual. The main toxicities included grade 1–2 abdominal pain, transient perioral numbness, nausea, and grade 1 thrombocytopenia. Two patients had grade 3 abdominal pain during cycle 2 infusion: one was hospitalized, and another was subsequently retreated at 80% dose without pain recurrence. Conclusions: Although this dose and administration schedule of DENSpm was quite tolerable, no evidence of clinical activity was detected. Encouraging preclinical activity of polyamine analogs alone and in combination with cytotoxic drugs supports the continued evaluation of newergeneration polyamine analogs for the treatment and prevention of breast cancer.

[1]  L. Marton,et al.  A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  P. Woster,et al.  The role of polyamine catabolism in anti-tumour drug response. , 2003, Biochemical Society transactions.

[3]  H. Wallace,et al.  Polyamine analogues as anticancer drugs. , 2003, Biochemical Society transactions.

[4]  M. Prados,et al.  Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  D. Neuberg,et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Hidalgo,et al.  A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  L. Marton,et al.  Novel Synthetic Polyamines Are Effective in the Treatment of Experimental Microsporidiosis, an Opportunistic AIDS-Associated Infection , 2002, Antimicrobial Agents and Chemotherapy.

[8]  P. Woster,et al.  Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. , 2001, Cancer research.

[9]  N. Davidson,et al.  Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  L. Marton,et al.  Conformationally restricted analogues of 1N,14N-bisethylhomospermine (BE-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cells. , 2001, Journal of medicinal chemistry.

[11]  J. O’Shaughnessy,et al.  α-Difluoromethylornithine as Treatment for Metastatic Breast Cancer Patients , 1999 .

[12]  D. Berry,et al.  Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Gerner,et al.  Development of difluoromethylornithine (DFMO) as a chemoprevention agent. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  N. Davidson,et al.  Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. , 1999, Endocrine-related cancer.

[15]  A. Buzdar,et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Gimotty,et al.  Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  R. Bergeron,et al.  Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  N. Davidson,et al.  Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. , 1995, Cancer research.

[19]  N. Davidson,et al.  Growth inhibition of hormone-responsive and -resistant human breast cancer cells in culture by N1, N12-bis(ethyl)spermine. , 1993, Cancer research.

[20]  J. Miller,et al.  Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action. , 1993, Cancer research.

[21]  M. Prados,et al.  Treatment of recurrent gliomas with eflornithine. , 1992, Journal of the National Cancer Institute.

[22]  R. Bergeron,et al.  Antitumor activity of N,N'-bis(ethyl)spermine homologues against human MALME-3 melanoma xenografts. , 1992, Cancer research.

[23]  R. Bergeron,et al.  Correlations between polyamine analogue-induced increases in spermidine/spermine N1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. , 1991, Cancer research.

[24]  R. Bergeron,et al.  Differential induction of spermidine/spermine N1-acetyltransferase in human lung cancer cells by the bis(ethyl)polyamine analogues. , 1989, Cancer research.

[25]  S. Baylin,et al.  Differential response to treatment with the bis(ethyl)polyamine analogues between human small cell lung carcinoma and undifferentiated large cell lung carcinoma in culture. , 1989, Cancer research.

[26]  A. Pegg,et al.  Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. , 1988, Cancer research.

[27]  F. Milord,et al.  DIFLUOROMETHYLORNITHINE FOR ARSENO-RESISTANT TRYPANOSOMA BRUCEI GAMBIENSE SLEEPING SICKNESS , 1987, The Lancet.

[28]  C. Levy,et al.  Urinary polyamines in cancer patients. , 1971, Cancer research.

[29]  R. Perez,et al.  Unusual central nervous system toxicity in a phase I study of N1N11diethylnorspermine in patients with advanced malignancy , 2004, Investigational New Drugs.

[30]  D. Ettinger,et al.  Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  J. Bender,et al.  Phase 1 study of N1-N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies. , 2001, Investigational new drugs.

[32]  P F Thall,et al.  A two-stage design for choosing among several experimental treatments and a control in clinical trials. , 1989, Biometrics.

[33]  J. Gray,et al.  Depletion of 9L rat brain tumor cell polyamine content by treatment with D,L-alpha-difluoromethylornithine inhibits proliferation and the G1 to S transition. , 1981, Experimental cell research.